A comparison of treatments offered to patients with nonalcoholic steatohepatitis by Iqbal, Saleem Perwaiz et al.
eCommons@AKU
Department of Paediatrics and Child Health Division of Woman and Child Health
December 2008
A comparison of treatments offered to patients with
nonalcoholic steatohepatitis
Saleem Perwaiz Iqbal
Aga Khan University
Sadia Mahmud
Aga Khan University
Saeed Hamid
Aga Khan University
Omrana Pasha
Aga Khan University
Khabir Ahmad
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_women_childhealth_paediatr
Part of the Pediatrics Commons
Recommended Citation
Iqbal, S., Mahmud, S., Hamid, S., Pasha, O., Ahmad, K. (2008). A comparison of treatments offered to patients with nonalcoholic
steatohepatitis. Journal of the College of Physicians and Surgeons Pakistan, 18(12), 744-50.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/8
744 Journal of the College of Physicians and Surgeons Pakistan  2008, Vol. 18 (12): 744-750
INTRODUCTION
Non-alcoholic Fatty Liver Disease (NAFLD) has become
an important disease entity owing to its common
occurrence in the general population and its potential to
progress to cirrhosis and hepatic failure. Nonalcoholic
steatohepatitis (NASH) is a form of NAFLD, which refers
to a wide spectrum of liver damage, ranging from simple
steatosis to advanced steatohepatitis and cirrhosis. 
Steatosis (fatty liver) is an accumulation of fat in the
liver, mostly triglycerides, exceeding 5-10% of the
weight of the liver.1 It is caused by a failure of normal
hepatic fat metabolism due to a defect either within the
hepatocyte or in the delivery of lipids from the liver
cells.2 Symptoms may include fatigue or malaise, and a
sensation of fullness or discomfort on the right side of
the upper abdomen.3 Hepatomegaly is a common
feature. Serum alanine aminotransferase may be
normal or high. Liver biopsy is the gold standard
technique to diagnose steatosis and steatohepatitis, but
it is an invasive procedure and associated with many
complications, which may become fatal. Imaging
techniques, like ultrasonography, though not the Gold
standard, are effective to diagnose fatty liver.3,4
Research shows that ultrasonography detects fatty liver
changes in 12.9%-16.4% of individuals.5
NAFLD affects all age groups; the greater predo-
minance is seen among male adults.6-8 The prevalence
of NAFLD averages about 10-30%, and that of NASH is
2-3% of the general population in many countries.1,5 The
prevalence may increase to approximately 50-70% in
the presence of risk factors such as obesity, Diabetes
mellitus, and dyslipidemia.3,4 An increase in body weight
is well correlated with the degree of fatty liver.4 Few
studies are in the context with the Asian Body Mass
Index (BMI), which defines new cut off points for
Asians.9
The pathogenetic mechanisms behind NASH
progression are not well-understood. However, it has
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ORIGINAL ARTICLE
been suggested that hepatic fatty infiltration is a
consequence of increased splanchnic lipolysis and
hepatic insulin resistance.10 Researchers suggest that
alteration of local and systemic factors, particularly
insulin resistance, that control the balance between the
synthesis of hepatic lipids and their oxidation lead to
hepatic triglyceride accumulation.5 This results in
hepatocellular inflammation and fibrosis. Other factors
like oxidative stress, adipocytokines, may provide
secondary insults, further complicating to steato-
hepatitis.11
Many factors have been identified to be associated with
NAFLD. It is commonly associated with metabolic
syndrome.4,12 It is reported that 60-95% of the NAFLD
patients are obese.4 Other causes may include
nutritional (starvation, total parenteral nutrition),
medicines (like amiodarone, corticosteroids, metho-
trexate), and diseases (like HIV infection, inflammatory
bowel disease etc.).3,5 It is conceivable from regional
data that NAFLD and NASH may also be very common
in Pakistan though no community-based studies have
been carried out.  
Currently, the treatment options for NASH are very
limited. The treatment modalities prescribed are focused
on modifying the associated conditions such as obesity,
dyslipidemia, and Diabetes mellitus.1,4,10 Weight loss
through diet restriction and exercise has proved to be
effective in various studies.3,5,10 The use of statins,
insulin sensitizing agents, anti-oxidants (like vitamin E),
and hepato-protective agents (such as pentoxifylline
and ursodeoxycholic acid), as a treatment modality for
NAFLD, are still being evaluated.1,10 There have been a
couple of reports on the use of Danning Pian (a Chinese
herbal medicine), and choline containing foods in the
treatment of NAFLD.13,14
This study attempts to compare various treatment
options being provided to patients with NASH, attending
the Aga Khan University Hospital (AKUH), Karachi, and
assess liver improvement through reduction in their
mean serum Alanine Aminotransferase (ALT) levels
overtime. 
METHODOLOGY
A retrospective cohort design was used to compare
various therapeutic options provided to patients with
NASH who attended the AKUH during the 7-year period
(April 2000 – April 2007), using the recorded data
collected from the Department of Health Information
Management Services, AKUH. The treatment options
were categorized as weight reduction only through the
advice of dietary restriction and engagement in regular
physical exercise, weight reduction and statins
(commonly prescribed were Simvastatin and
Atorvastatin), and weight reduction and other
medications, which were ursodeoxycholic acid (30.6%),
pioglitazone (22.4%), metformin (36.7%), and vitamin E
(10.2%). 
The diagnosis of NASH had been considered by the
attending gastroenterologist, based on unexplained
elevations in serum ALT, fatty liver on ultrasound and
upon excluding liver metabolic disorders (hemochro-
matosis, Wilson’s disease), auto-immune hepatitis and
viral infection.15 Serum ALT, one of the main liver
function enzymes, is of main interest towards assessing
improvement in liver status. This is measured
quantitatively in IU/l, recorded on at least one
subsequent follow-up after the initial visit. A maximum of
3 follow-ups were considered.
The inclusion criteria was to include all medical records
of the patients with NASH, with the age range of 20-70
years; fatty liver on ultrasound; and raised serum ALT
levels (for males greater than 55 IU/l; for females greater
than 33 IU/l). The exclusion criteria were pregnancy,
recent gastrointestinal surgery, history of alcohol
consumption, transfusion, drug abuse, and acute/
chronic infectious hepatitis, liver disorders, which would
account for steatosis other than NASH (Wilson’s
disease, hemochromatosis) and drugs which may also
result in liver steatosis (corticosteroids, methotrexate,
aspirin, etc.). Moreover, those individuals with no follow-
up after a baseline visit were also excluded from the
study.  
Height and weight was measured in SI units. The BMI
was assessed, according to the Asian standards, and
defined as < 18.5 kg/m2 as underweight, 18.5-23 kg/m2
as acceptable and 23.1-25 kg/m2 as overweight.9
Patients were also assessed for other comorbids such
as hypertension (systolic blood pressure exceeding 140
mmHg, and/or diastolic blood pressure exceeding 90
mmHg) and Diabetes mellitus (fasting serum glucose
levels exceeding 110 mg%).   
Serum ALT levels were the main outcome of interest
measured in IU/l. This was assessed on a quantitative
scale, among subjects with at least one follow-up after
the baseline visit. Demographic variables included age,
gender and marital status. Baseline characteristics
included patient history and family history of comorbid
conditions, such as Diabetes mellitus, hypertension,
dyslipidemia and hepatitis. Physical and laboratory
investigations included the physical components like
blood pressures, height and weight. The laboratory
investigations, in addition to liver function tests (serum
aspartate transaminase, ALT, and gamma glutamyl
transferase), also included total lipid profile (serum
levels of total cholesterol, triglycerides, LDL-cholesterol
and HDL-cholesterol) and serum glucose levels
(random and fasting serum glucose). 
In order to detect a minimum difference of 25 IU/l in the
ALT levels at last follow-up among the 3 treatment
groups at 80% power and 5% significance level, a
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minimum sample of 21 subjects per group was required.
The study was approved by the Ethics Review
Committee of the Aga Khan University. 
Data analysis was performed, using SPSS software for
Windows version 15 (SPSS Inc., Chicago, IL). Means
and standard deviations were calculated for quantitative
variables, and proportions for the categorical variables.
Baseline variables were compared among the
prescribed treatment options using one-way analysis of
variance. Non-parametric procedures were used for
non-normal data. Repeated-measures analysis of
variance, using a linear mixed model approach, was
performed with the treatment options as between
subject factor, and follow-up times as within subject
factor.15 Considering that the study subjects had
different number of follow-ups, it was particularly
relevant for this study to employ the mixed model
approach. The linear mixed model analyzes data in a
relational (longitudinal) format, permits flexibility in
modelling variance-covariance structures, and allows for
the analysis for variable number of follow-ups for each
patient. Serum ALT was the outcome assessed through
this approach. P-values at or < 0.05 were considered
significant.
RESULTS
Eighty-two records of patients were identified who
attended the hospital facility during the 7-year period
(April 2000 – April 2007), and were assessed for NASH.
Out of 82, 13 records were excluded for not meeting the
selection criteria. To avoid any potential selection bias,
the baseline demographic and clinical variables of the
excluded subjects were compared with those included in
the study (data not shown). The analysis demonstrated
that the major demographic and clinical characteristics
of the excluded subjects were not statistically different
from those included in the study (p > 0.05). The
remaining records (69) were analyzed for assessing the
outcome overtime.
Table I summarizes the frequency distribution of the
demographic and clinical variables. Out of 69, 50 (72%)
were males and 19 (28%) were females. Out of the total
65 (94%) were overweight, 9 (13%) were hypertensive,
44 (64%) were diabetic, and 48 (70%) had abnormal
serum lipid levels. Thirty-one out of 69 (45%) received
the treatment of weight reduction only, 12 (17%)
received statins along with advice for weight reduction,
and 26 (38%) received other medications along with
weight reducing advice. 
All subjects came with the primary concern of having
raised serum ALT on routine check-ups. In addition,
55% of the total also reported to have abdominal pain
and about 35% of the cases complained about fatigue
and weakness. Percentages of positive family history for
obesity, dyslipidemia, hepatitis, hypertension and
diabetes mellitus among cases were 37, 38, 40, 45 and
45, respectively. 
Tables II summarizes the clinical characteristics of
patients at baseline and at various follow-ups, for each
of the 3 prescribed treatments; weight reduction only,
weight reduction and statins, and weight reduction and
other medications, respectively. The mean age of the
group advised with weight reduction only was less than
that for the groups receiving statins and other
medications, in addition to weight reducing advice
(p=0.033; Table II). Mean systolic blood pressures at
baseline in the group receiving drugs along with weight
reduction were significantly greater than the group
receiving weight reducing advice only (p=0.003;
Table II). Similarly, mean diastolic pressures at baseline
in the group receiving other medications along with
weight reduction was also greater than the other groups
(p-value=0.047; Table II). This shows that the groups
receiving medications were relatively older and had
comorbids like hypertension. All the other clinical
characteristics were comparable among the 3 treatment
modalities at baseline.
A comparison of the subgroups receiving medications
other than statins revealed that mean baseline ALT
levels was highest in the groups receiving ursode-
oxycholic acid compared to subgroups on pioglitazone,
metformin and vitamin E (Table IIA). However, the
values reached the normal values in all the subgroups
within the 3rd follow-up. No other significant change was
observed in other parameters of these subgroups.
A declining trend overtime is observed for serum ALT
levels in all treatment groups (Figure 1). The group
being advised with weight reduction only showed a 72%
reduction in their serum ALT levels over the follow-up
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Table I: Frequency distribution of demographic and clinical charac-
teristics.
Variables Number (%)
Sex
Male 50 (72)
Female 19 (28)
Comorbids*
Hypertension 9 (13)
Overweight 65 (94)
Diabetes mellitus 44 (64)
Dyslipidemia 48 (70)
Treatment option
Weight reduction only 31 (45)
Weight reduction and statins 12 (17)
Weight reduction and other medications 26 (38)
Presenting complaints*
Raised serum ALT 69 (100)
Abdominal pain 38 (55)
Malaise and fatigue 24 (35)
Family history*
Obesity 26 (37)
Dyslipidemia 27 (38)
Hypertension 31 (45)
Diabetes mellitus 31 (45)
Hepatitis 28 (40)
* Multiple responses
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mean time of 9±3 months. The group being prescribed
with statins along with weight reducing advice showed a
56% reduction over a mean time of 11±7 months, while
the group receiving advice for weight reduction and
other medications experienced a 73% reduction in
serum ALT levels over a mean follow-up time of 10±4
months.
Mixed model analysis was performed with ALT as the
outcome (Table III). The model was adjusted for age and
gender, as the treatment groups differed with respect to
age at baseline, and the cut offs for raised ALT differed
for males and females. The mixed effect model shows
that the effect of follow-up times on mean ALT was
different for males and females (p=0.045). Males
encountered a 60% reduction in serum mean ALT
levels, while in females it got reduced by 64%. There
was no significant difference in mean ALT levels in the 3
treatment groups (p=0.352) and the mean ALT levels
decreased significantly overtime (p<0.001). No
significant interaction was observed between follow-up
times and the prescribed treatment (p=0.182) implying
that the reduction in mean serum ALT levels overtime is
not different for the different treatment options.
Table II: Clinical characteristics of patients receiving various treatments at baseline and various follow-ups (mean±SD).
Weight reduction only Weight reduction and statins Weight reduction and other medications
Variable* Baseline Follow- Follow- Follow- Baseline Follow- Follow- Follow- Baseline Follow- Follow- Follow-
up 1 up 2 up 3 up 1 up 2 up 3 up 1 up 2 up 3
Age (years) 36±9 - - - 46±15 - - - 43±12 - - -
Systolic blood pressure 
(mmHg) 117±13 118±14 115±8 94±5 131±13 126±14 119±18 135±7 128±13 132±15 125±14 118±16
Diastolic blood pressure 
(mmHg) 77±9 76±8 74±5 63±6 77±9 71±8 79±9 75±7 83±8 84±7 81±10 78±12
Weight (kg) 79±14 78±22 78±24 78±23 83±16 70±1 76±1 78±2 82±14 82±16 82±17 82±18
Body mass index (kg/m2) 29±5 28±7 28±8 28±7 29±4 29±2 30±5 34±5 30±5 30±5 30±5 31±5
ALT (IU/l) 95±40 57±31 46±24 26±16 101±55 76±33 60±26 44±20 90±38 56±27 35±15 30±12
AST (IU/l) 59±26 53±9 53±37 VSN 91±34 VSN 32±4 VSN 49±13 40±7 50±13 38±8
Total cholesterol (mg%) 181±68 199±65 183±53 VSN 203±70 233±50 190±79 126±117 197±23 178±51 154±32 VSN
Triglycerides (mg%) 163±95 169±51 147±52 VSN 142±102 334±299 294±257 171±198 206±104 179±81 177±55 VSN
LDL-cholesterol (mg%) 104±47 97±20 101±44 VSN 123±53 132±49 80±41 VSN 109±37 120±31 VSN VSN
HDL-cholesterol (mg%) 41±14 44±12 VSN VSN 38±5 43±19 36±9 VSN 41±8 43±13 VSN VSN
Random serum glucose 
(mg%) VSN VSN VSN VSN VSN VSN VSN VSN VSN 293±179 260±109 VSN
Fasting serum glucose 
(mg%) VSN VSN VSN VSN VSN 139±56 116±24 VSN VSN 161±45 VSN 68±81
* Mean age, systolic blood pressure and diastolic blood pressure were significantly different among the 3 groups (p value < 0.05)
** VSN = very small number of observations
Table II A: Clinical characteristics of patients receiving other medications at baseline and at various follow-ups (means±SD).
Ursodeoxycholic acid Pioglitazone Metformin Vitamin E
Variable Baseline Follow- Follow- Follow- Baseline Follow- Follow- Baseline Follow- Follow- Follow- Baseline Follow- Follow-
up 1 up 2 up 3 up 1` up 2 up 1 up 2 up 3 up 1 up 2
Age (years) 43±13 - - - 47±17 - - 43±12 - - - 38±12 - - 
Systolic blood pressure 
(mmHg) 126±13 133±15 126±12 126 ± 13 130±14 125±7 135±7 130±16 124±20 118±18 126±15 130±14 128±24 135±21
Diastolic blood pressure 
(mmHg) 85±8 86±8 84±8 84±9 80±11 75±7 80±14 84±9 81±8 75±12 69±10 86±10 85±13 88±11
Weight (kg) 83±11 83±11 83±14 90±16 88±23 83±20 84±20 79±16 78±16 78±18 67±10 85±5 84±5 85±7
Body mass index (kg/m2) 30±5 30±4 30±5 31±5 30±6 29±7 29±7 31±6 30±6 31±6 28±5 33±2 31±2 33±3
ALT (IU/l) 110±40 70±31 42±20 32±12 66±8 41±19 31±25 66±22 43±18 30±19 VSN 89±35 62±24 28±6
Table III: Mixed model analysis: fixed effects for ALT, adjusted for age
and sex.
Dependent variable Covariance structure P-value
ALT Unstructured
Age 0.195
Sex 0.011
Treatment 0.352
Follow-up time < 0.001
Sex * treatment 0.974
Sex * follow-up time 0.045
Treatment * follow-up time 0.182
Figure 1:  Mean alanine aminotransferase (ALT) at baseline and different
follow-ups with respect to treatment options.
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DISCUSSION
The primary objective of this study was to compare
various therapeutic options being provided to Pakistani
patients with nonalcoholic steatohepatitis and to assess
liver function improvement through reduction in serum
ALT levels. With the exception of a few small studies
carried out in India and Iran,16-18 there is hardly any
research data on this subject from this part of the world.
No research study of this kind has been conducted in
Pakistan. This study was carried out to derive
conclusions on assessing improvement in fatty liver
status with respect to treatment in Pakistani patients.
Majority of the patients in this study (n=31, 45%)
received the option of weight reduction only, which
remains the cornerstone treatment for nonalcoholic
steatohepatitis.3,19 In the presence of other co-morbid
conditions, pharmacological agents in addition to weight
reducing advice would be considered beneficial for
symptomatic patients. 
A significant decreasing trend in serum ALT levels with
follow-up time signifies improvement in NASH,
irrespective of the prescribed therapeutic modality.
Studies conducted elsewhere have also shown a similar
trend. For example, two small studies from India and
Iran showed a significant decline in serum ALT levels
with respect to time (p < 0.05) in different treatment
groups.17,18 A similar decline in liver enzymes has also
been reported in other studies carried out in some of the
developed countries.1,10,19 According to Marchesini et al.
weight reduction remains the treatment of choice for
patients with obesity.10 Since most of NASH patients in
this study were overweight, it was expected that a
reduction in BMI would occur in all 3 groups and would
correspond to the decline in serum ALT levels. However,
no decline in BMI was observed over a mean period of
10±5 months in all the three groups. Poor compliance on
the part of the patients to prescriptive advice could have
been the reason for little change in mean BMI. However,
this was not unique to our patient population. Similar
findings have also been reported in other studies.1,4,18,20 
NASH patients usually present with vague symptoms.3
In this study, the presentation of the disease was
asymptomatic in majority of the cases, while some
reported with mild abdominal pain and fatigue. Male
preponderance observed in this study has also been
reported by others.5,17 This could be due to genetic
differences among various populations or females from
the subcontinent might have been more hesitant in
seeking treatment for a relatively asymptomatic disease,
like NASH. Bahrami et al. suggested that exclusion of
subjects with hepatitis might have been the reason for
the gender differences.17 In the present study too the
diagnosis of NASH was made on patients after ruling out
hepatitis. 
Dyslipidemia (70%) and Diabetes mellitus (64%) were
common in the study subjects. This is also consistent
with other similar studies.17,19,20 Among diabetics, data
suggested that about 60% were using diabetic
medications, metformin and pioglitazone, separately or
combined. However, this may not have affected the
progression of NASH as those latter medications are
recommended for treatment of this disease. 
The data revealed a number of risk factors (obesity,
hypertension, diabetes, dyslipidemia), which contributes
to NASH.20-22 A recent study conducted in a tertiary care
hospital in Islamabad showed an increased prevalence
of metabolic syndrome,23 a primary risk factor for NASH.
Since the individual components of metabolic syndrome
are reaching epidemic proportions in Pakistan, hence
the prevalence of NASH would also be expected to be
high in our population.    
No significant decline in BMI overtime in this study
merits some discussion. It is suggestive that greater
follow-up time would, perhaps, be necessary to examine
any significant change in BMI due to treatment.
Bugianesi et al. in their trial followed their subjects for
one year, with a 3 month follow-up time, and
demonstrated a declining trend in BMI.19 Georgescu et
al. followed their subjects for 37-38 weeks (8-9 months),
and observed a slight declining trend.1 By extending the
follow-up time, and ensuring better compliance by
patients would, perhaps, be necessary to evaluate any
beneficial effects of weight reduction in NASH.
There were a few limitations of this study. Being a
retrospective cohort study, it was not unusual to find
some laboratory values like serum ALT, AST, serum
cholesterol, serum triglycerides, serum fasting and
random glucose levels to be missing at consecutive
follow-up times. In order to address the issue of missing
values at follow-up times, the mixed model analysis was
performed for ALT, as the data measurements for this
variable were sufficient to conduct this advanced
analysis. For the other laboratory markers of liver
function, the amount of missing data was comparatively
larger and so mixed model analyses could not be
performed. 
Recording of data on the treatment options for NASH
offered another limitation to the study. Generally,
prescriptions on weight reduction tend to be more
verbose compared to that of drugs, which may result in
misclassification of the subjects. However, for the
patients assessed for NASH in this study, such advices
and prescriptions were mostly available on record, thus
minimizing misclassification.
As mentioned earlier, no proven therapy exists for
NASH, and so there is much debate on the options of
treatment as well as their duration. Assessment of
compliance of subjects to the provided treatment is also
questionable, as there may be a possibility for subjects’
crossing over on the provided options for treatment. 
Serum ALT was used as a laboratory surrogate marker
to evaluate improvement in NASH. Though changes in
serum ALT can be useful as a surrogate in screening
therapies for NASH with baseline ALT levels and
histology,24 however, using this as the only laboratory
surrogate may be considered as another limitation.
Previous research reports suggest that other liver
function enzymes, especially AST, also assist in
identifying steatosis and steatohepatitis.20 We
attempted to incorporate other liver function enzymes,
but the missing data did not permit us to do that. Since
serum levels for both AST and ALT fluctuate, therefore,
variability is anticipated. Other non-invasive markers,
like serum hyaluronic acid, ketoisocaproate breath test,
are still under research, and may provide better
directions towards assessing liver improvement in
NASH, non-invasively.25,26 According to Portincasa et al.
liver breath testing using ketoisocaproate and
methacetin isotopes can be clinically useful to
characterize NASH.25
Mean ages of patients among the three treatment
groups were not comparable. However, the mixed
model analysis allowed us to adjust for age in the final
effect model. Variability in the follow-up time intervals for
various patients and small sample size in the group
receiving weight reduction and statins were other
limitations in the study. The small sample size resulted
in decreased power and, therefore, the mixed model
analysis may not have been able to detect significant
differences with respect to the treatment groups. A
prospective study using a large number of well-defined
NASH patients and a follow-up of greater than 12
months would, perhaps, be necessary to ascertain
whether pharmacological treatment in addition to weight
reduction has any advantage over the standard weight
reduction treatment in Pakistani population.
CONCLUSION
Serum ALT levels among patients with NASH decreased
significantly with time, irrespective of the provided
treatment option, and the decline differed between
males and females. More epidemiological research in
this field would be essentially required to understand the
nature of disease in this part of the world and to offer
better treatment options.
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